STOCK TITAN

Director at QuidelOrtho (QDEL) receives 1,407 shares from RSU release

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

QuidelOrtho Corp director Ann D. Rhoads reported routine equity compensation activity. She received a total of 1,407 shares of common stock on May 22, 2026 through the release of previously reported restricted stock units.

Footnotes state these restricted stock units each convert into one share of common stock and that their release was deferred under QuidelOrtho’s deferred compensation program for participating non-employee directors, occurring according to her elected deferral schedule. The filing shows no open‑market purchases or sales, only grants and conversions of equity awards.

Positive

  • None.

Negative

  • None.
Insider RHOADS ANN D
Role null
Type Security Shares Price Value
Exercise Restricted Stock Units (Converted) 1,173 $0.00 --
Exercise Restricted Stock Units (Premium) 234 $0.00 --
Grant/Award Common Stock 1,173 $0.00 --
Grant/Award Common Stock 234 $0.00 --
Holdings After Transaction: Restricted Stock Units (Converted) — 0 shares (Direct, null); Restricted Stock Units (Premium) — 0 shares (Direct, null); Common Stock — 16,194 shares (Direct, null)
Footnotes (1)
  1. Reflects release of restricted stock units that were previously reported on a Form 4. Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. Release of restricted stock units was deferred pursuant to QuidelOrtho's deferred compensation program applicable to participating non-employee directors and occurred according to the elected deferred schedule.
Common shares from RSU release 1,407 shares Total common stock received on May 22, 2026
First award share amount 234 shares Common Stock credited at $0.00 per share
Second award share amount 1,173 shares Common Stock credited at $0.00 per share
Derivative exercises 1,407 shares Exercise of restricted stock units into common shares
Restricted Stock Units financial
"Reflects release of restricted stock units that were previously reported on a Form 4."
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
deferred compensation program financial
"Release of restricted stock units was deferred pursuant to QuidelOrtho's deferred compensation program applicable to participating non-employee directors"
non-employee directors financial
"deferred pursuant to QuidelOrtho's deferred compensation program applicable to participating non-employee directors"
Non-employee directors are board members who do not work for the company as salaried employees and usually do not hold day-to-day management roles. They act like outside referees or independent coaches, providing oversight, asking tough questions, and protecting shareholders’ interests; investors care because these directors help ensure management is accountable, reduce conflicts of interest, and influence decisions that affect company strategy and long-term value.
Exercise or conversion of derivative security financial
"transaction_code_description": "Exercise or conversion of derivative security""
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
RHOADS ANN D

(Last)(First)(Middle)
9975 SUMMERS RIDGE ROAD

(Street)
SAN DIEGO CALIFORNIA 92121

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
QuidelOrtho Corp [ QDEL ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/22/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock05/22/2026A1,173(1)A$016,194D
Common Stock05/22/2026A234(1)A$016,428D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Restricted Stock Units (Converted)(2)05/22/2026M1,173 (3) (3)Common Stock1,173$00D
Restricted Stock Units (Premium)(2)05/22/2026M234 (3) (3)Common Stock234$00D
Explanation of Responses:
1. Reflects release of restricted stock units that were previously reported on a Form 4.
2. Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock.
3. Release of restricted stock units was deferred pursuant to QuidelOrtho's deferred compensation program applicable to participating non-employee directors and occurred according to the elected deferred schedule.
Remarks:
/s/ Phillip S. Askim, attorney-in-fact for Ann D. Rhoads05/27/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did QuidelOrtho (QDEL) report for Ann D. Rhoads?

QuidelOrtho reported that director Ann D. Rhoads received equity compensation. She acquired 1,407 common shares through the release and conversion of previously reported restricted stock units on May 22, 2026, with no open‑market buying or selling involved.

How many QuidelOrtho (QDEL) shares did Ann D. Rhoads acquire in this Form 4?

Ann D. Rhoads acquired 1,407 QuidelOrtho common shares in total. The filing shows 234 shares and 1,173 shares credited to her, both at a price of $0.00 per share, reflecting equity compensation rather than market purchases.

What role did restricted stock units play in the QuidelOrtho (QDEL) Form 4?

The Form 4 centers on restricted stock units converting into common stock. Footnotes explain each unit equals one QuidelOrtho common share, and the reported transactions reflect the release of these units that had been reported previously on an earlier Form 4.

Was the QuidelOrtho (QDEL) director transaction linked to a deferred compensation program?

Yes. Footnotes state the restricted stock unit release was deferred under QuidelOrtho’s deferred compensation program for participating non‑employee directors and occurred according to Ann D. Rhoads’ elected deferral schedule, indicating a pre‑set compensation timing choice.

Did Ann D. Rhoads buy or sell QuidelOrtho (QDEL) shares on the open market?

The Form 4 does not show any open‑market trades by Ann D. Rhoads. All reported entries are coded as awards or derivative exercises, meaning they relate to equity compensation grants and restricted stock unit conversions rather than discretionary market purchases or sales.